REOLYSIN® in patients with sarcomas with lung metastases

[Olga]

4/11/2007 2:00:00 AM ET News Release Index

Oncolytics Biotech Inc. Proceeds to Initiate U.S. Phase II Sarcoma Clinical Trial

CALGARY, AB, --- April 11, 2007 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that subsequent to the regulatory review period for this submission, it is proceeding with a Phase II trial to evaluate the intravenous administration of REOLYSIN® in patients with various sarcomas that have metastasized to the lung. The Principal Investigators are Dr. Glenn S. Kroog of the Montefiore Medical Center/Albert Einstein College of Medicine in the Bronx, New York, Dr. Laurence H. Baker of the University of Michigan Comprehensive Cancer Center in Ann Arbor, and Dr. Monica Mita of the Cancer Therapy and
Research Center, Institute for Drug Development in San Antonio, Texas.
The link to the Oncolytics Biotech Inc. is http://www.oncolyticsbiotech.com/index.html
this message is in the http://www.integratir.com/newsrelease.asp?ticker=t.onc

[cricri]

Hello,
I would like to know what you think of test clinical with the reolysin. Is too early to integrate this tests. Optimistic the results can one be.

Thank you for your opinion,

Cricri

[Olga]

CriCri - there are a few clinical trials at the moment shown on the clinicaltrials.gov where ASPS specifically named for the enrolment - beside vaccine at Dana Farber - they test Dasatinib, perifosine and brostallicin - but we have no any idea why ASPS is named as a possible target and if it is based on a research or what. They do not give any explanations and we are not in the position to recommend or not recommend to our people any of these clinical trials. We have no knowledge about any of our people participating in these trials.